We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epitomics, Inc. and University of California, Davis, Complete Star Program
News

Epitomics, Inc. and University of California, Davis, Complete Star Program

Epitomics, Inc. and University of California, Davis, Complete Star Program
News

Epitomics, Inc. and University of California, Davis, Complete Star Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epitomics, Inc. and University of California, Davis, Complete Star Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Over the course of the project, more than 100 rabbit monoclonal antibodies (RabMAbs) raised against clinical cancer biomarkers were analyzed and determined to possess affinities ranging from 10-9 to 10-13 M, with an average of 10-10 M. The affinity values measured using this label-free optical microarray detection process were found to be consistent with those measured using the established BIAcore technology, based on a random sampling of the RabMAb population.

"I am very excited about our new technology which can provide consistent results compared to the established BIAcore technology but in a high throughput manner. I am also impressed with high affinities of RabMAbs" said Dr. Xiangdong Zhu, a Professor in Physics at the University of California, Davis, who was the inventor of the label-free optical microarray detection technology used in the program.

"It is widely accepted that rabbits produce higher affinity antibodies than mice, but this had not previously been demonstrated with a large population of monoclonal antibodies. With the availability of this novel technology, we were able to demonstrate that RabMAbs have consistently high affinities through the measurement of a large collection of RabMAbs" said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

Advertisement